Austria vs North Macedonia: Average non-HDL cholesterol levels
Austria
3.6
in 2018
North Macedonia
3.6
in 2018
Austria rank
30th
North Macedonia rank
30th
Average non-HDL cholesterol levels over time
- Austria
- North Macedonia
How they compare
Austria currently reports 3.6 against 3.6 in North Macedonia, a difference of 0.
The two have swapped places 5 times across 39 shared years of data; in 1980 it was Austria ahead.
Austria ranks 30th and North Macedonia ranks 30th of 191 countries.
Across the 4 decades both report, Austria averaged higher in 3 and North Macedonia in 1.
Head to head by decade
| Decade | Austria | North Macedonia | Difference | Ahead |
|---|---|---|---|---|
| 1980s | 4.48 | 4.2 | 0.28 | Austria |
| 1990s | 4.29 | 4.1 | 0.19 | Austria |
| 2000s | 3.95 | 3.9 | 0.05 | Austria |
| 2010s | 3.7 | 3.71 | 0.0111 | North Macedonia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average non-hdl cholesterol levels, Austria or North Macedonia?
- Austria, at 3.6 against 3.6 in North Macedonia as of 2018.
- What is the difference in average non-hdl cholesterol levels between Austria and North Macedonia?
- 0, with Austria ahead.
- How many years of comparable data are there for Austria and North Macedonia?
- 39 years are reported by both, from 1980 to 2018.
- How do Austria and North Macedonia rank globally for average non-hdl cholesterol levels?
- Austria ranks 30th and North Macedonia ranks 30th of 191 countries.
- Where does this data come from?
- World Health Organization – Global Health Observatory (2026) – with minor processing by Our World in Data, published as Average non-HDL cholesterol levels. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The estimated average level of non-high-density lipoprotein (non-HDL) cholesterol, commonly known as "bad cholesterol". Healthy levels are considered to be under 4mmol/L. Elevated levels of non-HDL cholesterol are a risk factor for chronic complications, including cardiovascular disease, and premature death.